AbbVie and Swiss drug giant Roche Holding are jointly developing venetoclax, which is sold under the brand names Venclexta and Venclyxto and approved for indications in chronic lymphocytic leukemia and acute myeloid leukemia.

Source: https://www.marketscreener.com/quote/stock/ABBVIE-INC-12136589/news/AbbVie-Phase-3-Venetoclax-Dexamethasone-Study-Falls-Short-in-Multiple-Myeloma-44952641/?utm_medium=RSS&utm_content=20230929

AbbVie comprises 2.3% of Schrum Private Wealth Management LLC’s investment portfolio, making the stock its 8th biggest holding.

Source: https://www.americanbankingnews.com/2023/01/06/abbvie-inc-nyseabbv-shares-sold-by-schrum-private-wealth-management-llc.html

AbbVie Inc., Alma Lasers GmbH, AngioDynamics Inc., Bausch Health Co Inc., Boston Scientific Corp., Candela Corp, Cutera Inc., Cynosure LLC, El.

Source: https://www.prnewswire.com/news-releases/energy-based-non-invasive-medical-aesthetic-treatment-system-market-size-to-grow-by-usd-1-841-74-million-from-2022-to-2027-growth-driven-by-rising-awareness---technavio-301716666.html

AbbVie Inc. has a 52-week low of $134.09 and a 52-week high of $168.11.

Source: https://www.etfdailynews.com/2023/04/15/abbvie-inc-nyseabbv-shares-sold-by-meyer-handelman-co/

AbbVie Inc. has a one year low of $131.10 and a one year high of $168.11.

Source: https://www.etfdailynews.com/2023/06/15/abbvie-inc-nyseabbv-shares-sold-by-ima-wealth-inc/

AbbVie Inc. (NYSE:ABBV) Shares Sold by McKinley Carter Wealth Services Inc.

Source: https://www.americanbankingnews.com/2023/01/02/abbvie-inc-nyseabbv-shares-sold-by-mckinley-carter-wealth-services-inc.html

AbbVie makes up 1.1% of Global Assets Advisory LLC’s investment portfolio, making the stock its 27th biggest holding.

Source: https://www.dailypolitical.com/2023/10/03/abbvie-inc-nyseabbv-shares-acquired-by-global-assets-advisory-llc.html

AbbVie will take the lead on therapeutic cargo, and will lead clinical development and commercialization.

Source: https://medcitynews.com/2023/02/abbvie-pays-capsida-70m-to-expand-gene-therapy-alliance-to-eye-diseases/

Aberdeen Wealth Management LLC trimmed its stake in shares of AbbVie Inc. () by 0.6% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission.

Source: https://www.dailypolitical.com/2023/09/12/abbvie-inc-nyseabbv-shares-sold-by-aberdeen-wealth-management-llc.html

Arrowstreet Capital Limited Partnership increased its holdings in AbbVie by 426.5% in the first quarter.

Source: https://www.americanbankingnews.com/2023/01/05/galvin-gaustad-stein-llc-sells-5796-shares-of-abbvie-inc-nyseabbv.html

As a group, sell-side analysts expect that AbbVie Inc. will post 13.98 earnings per share for the current fiscal year.

Source: https://www.americanbankingnews.com/2023/01/06/abbvie-inc-nyseabbv-shares-acquired-by-veriti-management-llc.html

Beginning in 2023, AbbVie will be responsible for funding the majority of all RGX-314 development expenses.

Source: https://seekingalpha.com/article/4583169-regenxbio-inc-rgnx-q4-2022-earnings-call-transcript?source=feed_all_articles

C2C Wealth Management LLC grew its holdings in shares of AbbVie by 1.7% during the 2nd quarter.

Source: https://www.dailypolitical.com/2023/10/01/optas-llc-reduces-stake-in-abbvie-inc-nyseabbv.html

California Public Employees Retirement System raised its position in AbbVie by 6.1% in the fourth quarter.

Source: https://www.dailypolitical.com/2023/06/11/abbvie-inc-nyseabbv-stock-holdings-increased-by-amundi.html

Capital International Investors raised its position in shares of AbbVie by 162.6% in the 1st quarter.

Source: https://www.americanbankingnews.com/2023/01/09/coastal-investment-advisors-inc-increases-stock-position-in-abbvie-inc-nyseabbv.html

Checchi Capital Advisers LLC’s holdings in AbbVie were worth $3,089,000 at the end of the most recent reporting period.

Source: https://www.etfdailynews.com/2023/11/15/checchi-capital-advisers-llc-sells-558-shares-of-abbvie-inc-nyseabbv/

CX Institutional raised its stake in shares of AbbVie Inc. () by 29.1% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC).

Source: https://www.dailypolitical.com/2023/12/28/cx-institutional-increases-stake-in-abbvie-inc-nyseabbv.html

Delta Financial Group Inc. boosted its stake in shares of AbbVie by 1.2% during the 1st quarter.

Source: https://www.dailypolitical.com/2023/10/03/abbvie-inc-nyseabbv-shares-bought-by-mcdaniel-terry-co.html

Equities research analysts forecast that AbbVie Inc. will post 10.97 earnings per share for the current year.

Source: https://www.americanbankingnews.com/2023/03/22/abbvie-inc-nyseabbv-shares-sold-by-gofen-glossberg-llc-il.html

Ergoteles LLC lifted its position in shares of AbbVie by 17.8% during the first quarter.

Source: https://www.americanbankingnews.com/2023/03/19/abbvie-inc-nyseabbv-shares-sold-by-mr-capital-management-inc.html